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London, London, UKA B S T R A C TObjectives: Dietary salt intake has been causally linked to high blood
pressure and increased risk of cardiovascular events. Cardiovascular
disease causes approximately 35% of total UK deaths, at an estimated
annual cost of £30 billion. The World Health Organization and the
National Institute for Health and Care Excellence have recommended a
reduction in the intake of salt in people's diets. This study evaluated the
cost-effectiveness of four population health policies to reduce dietary
salt intake on an English population to prevent coronary heart
disease (CHD). Methods: The validated IMPACT CHD model was used
to quantify and compare four policies: 1) Change4Life health promotion
campaign, 2) front-of-pack trafﬁc light labeling to display salt content, 3)
Food Standards Agency working with the food industry to reduce salt
(voluntary), and 4) mandatory reformulation to reduce salt in processed
foods. The effectiveness of these policies in reducing salt intake, and
hence blood pressure, was determined by systematic literature review.
The model calculated the reduction in mortality associated with eachee front matter Copyright & 2014, International S
r Inc.
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BA, UK.policy, quantiﬁed as life-years gained over 10 years. Policy costs were
calculated using evidence from published sources. Health care costs for
speciﬁc CHD patient groups were estimated. Costs were compared
against a “do nothing” baseline. Results: All policies resulted in a life-
year gain over the baseline. Change4life and labeling each gained
approximately 1960 life-years, voluntary reformulation 14,560 life-years,
and mandatory reformulation 19,320 life-years. Each policy appeared
cost saving, with mandatory reformulation offering the largest cost
saving, more than £660 million. Conclusions: All policies to reduce
dietary salt intake could gain life-years and reduce health care expendi-
ture on coronary heart disease.
Keywords: cardiovascular disease, economic evaluation, population
health, salt, UK policy.
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Cardiovascular disease (CVD) continues to be a major cause of
mortality and morbidity in the United Kingdom. The main forms
of CVD are coronary heart disease (CHD) and stroke. Approxi-
mately 35% of total UK deaths are attributable to CVD, at an
estimated annual cost of £30 billion to the UK economy [1], with
£14.4 billion being spent on treatments [2]. High levels of dietary
salt intake promote high blood pressure, which is a leading cause
of CHD [3]. Attention is therefore turning toward developing CVD
prevention policies, including substantially reducing dietary salt
intake [4]. In the United Kingdom, the average daily salt intake
has subsequently fallen from 9.5 g/d in 2000-2001 to 8.1 g/d in
2011 [5]. This remains, however, well above the 6 g/d maximum
recommended by the Scientiﬁc Advisory Committee on Nutrition
[6]. There is therefore considerable scope to develop policies that
focus on further reducing salt intake within the population.A review of the existing literature on the cost-effectiveness of
population health interventions to reduce dietary salt intake found
that most of the articles used modeling techniques to analyze the
effects of population health interventions. One article, however, has
summarized data from two studies that were implemented in two
different community settings: North Karelia, Finland, and the
Stanford 5 City Project, America. These interventions included
health education, screening, and a hypertension control and treat-
ment program in these community settings [7]. The North Karelia
study saw a 73% drop in CHDmortality in the region and also a drop
in the rest of Finland over the 25-year follow-up period. In the
Stanford 5 City Project, there were also useful reductions in
cholesterol, blood pressure, and smoking rates compared with sites
that did not have the intervention.
The studies that have used modeling techniques have suggested
that legislation for reducing salt intake appears more effective than
voluntary agreements [8]. In America, government collaborationociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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sodium intake. It was estimated that more than 2 million quality-
adjusted life-years (QALYs) and more than $32 billion in medical
costs could be saved [9]. Another US study quantiﬁed the beneﬁts of
a population-wide reduction in salt of up to 3 g/d, and estimated
annual savings of $10 billion to $24 billion and 44,000 fewer deaths
[10]. A recent UK analysis estimated that reducing daily salt intake
by 3 g might result in substantial savings in QALYs and health care
expenditure [11]. This study did not, however, consider exactly how
such salt reductions might actually be achieved. In contrast, a recent
study conducted in four Eastern Mediterranean countries explicitly
compared three policies to reduce salt intake: a health promotion
campaign, labeling of food packaging, and mandatory reduction of
salt content in processed foods. Most of these policies appeared cost
saving compared with the baseline of doing nothing [12].
To implement more effective policies in future, UK policymakers
will need robust and convincing evidence to assess the costs and
beneﬁts of speciﬁc interventions. The objective of this article was to
analyze the potential effect on health outcomes of reducing dietary
salt intake in an English population. We used an existing model to
quantify and compare four population interventions: a health
promotion campaign, labeling of foods, and both voluntary and
mandatory reformulation.Methods
Salt Reduction Policies for Evaluation
There are currently policies being implemented in the United King-
dom that raise awareness of the beneﬁts of reducing salt intake and
also encourage people to change their dietary habits. These policies
include a health promotion campaign called Change4Life, which was
launched in 2009 as the social marketing part of the Healthy Weight,
Healthy Lives strategy for England [13]. This campaign used a range
of media, including TV and radio advertisements and print media, to
encourage people to get active and to promote healthier food
choices, with a focus on increasing fruit and vegetable consumption
and reducing the consumption of foods high in fat, sugar, and salt. In
addition, food labeling is now a requirement in the United Kingdom
to inform consumers about the nutritional content of the food they
buy [14]. UK Food manufacturers and retailers are increasingly using
the Trafﬁc Light System on food packaging, on which red, amber,
and green color codes are used to indicate the levels of fats, sugars,
and salt [15]. A potentially confusing variety of schemes currently
exist, however, and a standardized approach across all food manu-
facturers has not yet been implemented. This is highlighted by the
recent Department of Health recommendations on the use of a
single “trafﬁc light” nutritional labeling system [16].
In the United Kingdom, 75% of the salt eaten comes from
processed foods [17]. This led to the Food Standards Agency (FSA)
launching a health promotion campaign in 2003 alongside working
with the food industry to encourage reformulation of processed
foods on a voluntary basis. The ﬁrst salt targets were set in 2006,
and subsequently replaced with new targets to be met by 2012.
These policies outlined above are currently being implemented in
the United Kingdom. There is little evidence, however, on the
relative cost-effectiveness of speciﬁc policies. Such evidence is
crucial to direct future policy on salt reduction to reach the
recommended daily maximum of 6 g/d [6].
We have chosen to evaluate these policies, three of which have
already been shown to be feasible in the United Kingdom. These are
1) the Change4Life health promotion campaign that encourages
people to eat less and get active, 2) front-of- pack labeling to display
the salt content of food using a standardized trafﬁc light system to
help consumers to make more informed purchasing decisions, 3)
the FSA continuing to work with the food industry to reformulateproducts on a voluntary basis, and 4) mandatory reformulation of
processed foods with legislation in place.
Effectiveness of Salt Reduction Policies
The effectiveness of these policies can be expressed as the percent-
age decrease in dietary salt intake achievable from each policy.
Limited information on the effectiveness of voluntary reformulation
was already available from successive National Diet and Nutrition
Surveys [5]. These surveys are used as a way of monitoring the
ongoing effect of the FSA’s work in reducing salt in processed food.
Therefore, an assumption has been made that these surveys were
capturing the reduction of salt intake from the FSA’s work with
industry on a voluntary basis. A further assumption was made that
voluntary measures alone would not achieve 100% compliance
across industry, whereas a mandatory approach might be expected
to be more effective, reducing consumption by at least 20%. For the
other policies, information on the effectiveness was obtained from
published studies. The literature review focused on the cost-
effectiveness of population health interventions and articles that
reported estimates of the effectiveness of each policy. Databases
searched include MEDLINE, Jstor, Cochrane, and the National Health
Service Economic Evaluation Database (see Appendix 1 for the search
strategies in Appendix 1 for the search strategies in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.03.1722).
For each policy, a “best” estimate was selected from the
systematic review. The ﬁnal effectiveness estimates used in the
analysis are presented in Table 1. The best estimates for options
1, 2, 3, and 4 were assumed to be 2%, 2%, 15%, and 20%,
respectively. To account for uncertainty around each best esti-
mate, a minimum and maximum value was also included to
provide a range of potential effect sizes for each policy (Table 1).
Health Outcomes
We extended the current IMPACT CHD model calibrated for the
English population to estimate the effect of different salt reduc-
tion policies on mortality and on life-years [18].
Data Sources for the IMPACT CHD Model
Mortality and demographic data were obtained from the Ofﬁce
for National Statistics. Patient numbers were estimated for seven
mutually exclusive patients groups: acute myocardial infarction
admissions, unstable angina admissions, secondary prevention
after acute myocardial infarction, secondary prevention after
revascularization, angina in the community, heart failure admis-
sions (hospital), and heart failure (community), with data from
Hospital Episode Statistics, the Myocardial Ischemia National
Audit Project [19], and the General Practice Research Database.
Systolic blood pressure levels were obtained from the Health
Survey for England [20]. Further details on data sources can be
obtained from Bajekal et al. [21] and Appendix 2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.03.1722.
IMPACT CHD Model Methods
The expected change in salt intake (as presented in Table 1) was
translated into a change in blood pressure on the basis of a large
meta-analysis, taking into account the differential effect on systolic
blood pressure (SBP) of salt intake reduction among hypertensive and
nonhypertensive persons [3]. The nonhypertensive persons were
split into the sevenmutually exclusive patient groups outlined above.
The expected number of deaths in 2020 was calculated by
estimating 2020 rates using an exponential decay regression model
ﬁtted to past mortality rates observed from 1993 to 2010. This model
captures how CHDmortality rates decrease over time while avoiding
unrealistic negative values. In the regression approach used for SBP,
Table 1 – Effectiveness of policies to reduce dietary salt intake.
Policy Details of intervention Best
estimate
[min, max]
Study
references
Health promotion
campaign—
Change4life
Advertising (media) campaign promoting healthy eating and physical activity. 2% [1%, 5%] [17–19]
Labeling All food packaging would be required to carry labeling to show the salt
content as well as other nutritional values using a uniform trafﬁc light
labeling system. Monitoring of labels would be required.
2% [1%, 5%] [17]
Reformulation—
voluntary
Salt targets set by the FSA for the reformulation of food products by
manufacturers to reach by 2012. These targets are set for food product
categories, with subcategories where relevant. Monitoring of this policy is
in progress using urinary analysis and monitoring of food labels.
15% [5%, 20%] [4,20]
Reformulation—
mandatory
Introducing a legislation to impose salt reduction targets on food
manufacturers. Monitoring of salt intake levels through urinary analysis
and monitoring of food labels would be required.
20% [10%, 32%] [20]
FSA, Food Standards Agency.
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multiplied by the absolute change in risk factor prevalence, and by a
regression coefﬁcient quantifying the change in CHD mortality that
would result from the change in SBP levels. Natural logarithms were
used, as is conventional, to best describe the log-linear relationship
between changes in risk factor levels and mortality.
In another meta-analysis [22], it was reported that there is an
estimated age- and sex-speciﬁc reduction in vascular mortality of
50% for every 20 mm Hg reduction in SBP, which generated a
logarithmic coefﬁcient. This coefﬁcient was then used along with
the change in SBP, and the expected number of deaths in 2020, to
calculate the number of deaths prevented or postponed (DPPs) for
men and women in each age group [22]. Further explanation of
the DPP calculation is outlined in Appendix 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.03.1722.
We then estimated the number of life-years gained (LYGs) by
multiplying the policy’s estimated DPPs by the age-speciﬁc median
survival for the different population subgroups (diagnosed CHD,
undiagnosed CHD, and population free of CHD). Estimates of
median survival were obtained from a previous analysis performed
for England and Wales population for 2000 [18,23–25].Costs
Salt Reduction Policies
The costs to the public sector of introducing each policy and the
costs to the private sector of labeling and reformulating productsTable 2 – Ten-year discounted policy and monitoring cos
Policy Policy costs (£)
Baseline 0
Change4Life 41,605,237
Labeling 19,323,671
Reformulation—voluntary 0
Reformulation—mandatory (best case) 0
Reformulation—mandatory (worst case) 483,091,787were included. The cost of each policy was assessed using published
evidence where available, and the cost of each policy over 10 years
was then calculated. The discounted costs are shown in Table 2,
and the total costs are shown in Appendix 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.03.1722.
The costs for the Change4Life health promotion media cam-
paign were obtained from the Department of Health (Freedom of
Information request to Department of Health, 2012). The total
cost for the campaign for each year since 2009 until 2012 included
advertising (television commercials, newspaper advertising, and
posters), digital and print media, communications planning,
public relations, and regional events. The budget did not include
staff costs. These costs were assumed to continue every year in
the same pattern. A box of all the assumptions used in the
analysis is presented in Appendix 5 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.03.1722.
The labeling of foods varies because of various factors includ-
ing the size of the business in question and the type of label used
on the packaging in terms of material and colors used. The
average cost of labeling per Stock Keeping Unit (a food product
with its own unique bar code) was taken from the FSA Impact
Assessment 2009 and was estimated at £1,000. This ﬁgure was
then used with the estimated 20,000 reformulated product lines
that will require a change of label to a uniform trafﬁc light system
to calculate an overall cost for labeling.
The FSA’s Impact Assessment 2009 for the voluntary refor-
mulation strategy includes a ﬁgure of £25,000 for the reformula-
tion of one product as supplied by the British Retail Consortium.
The FSA states that because of the voluntary nature of thets.
Monitoring costs (£) Total cost (£)
0 0
0 41,605,237
17,527,929 36,851,600
17,527,929 17,527,929
17,527,929 17,527,929
17,527,929 500,619,716
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manufacturers because many products are reformulated within
a natural product cycle; therefore, the cost for voluntary refor-
mulation includes only the monitoring costs. Although this view
was taken, the FSA attempted to estimate the cost of reformula-
tion for industry by using information from the larger UK retailers
and other stakeholders to provide a best estimate of the number
of lines reformulated within the processed foods categories. This
was estimated at 20,000 product lines.
Imposing legislation on food manufacturers to reduce salt
levels in processed foods would result in a requirement for
manufacturers to reformulate many products outside of natural
product cycles and thus could potentially result in additional
costs to manufacturers. It is difﬁcult to estimate the exact cost of
reformulation for manufacturers; therefore, to provide a balanced
idea of the costs of legislation we have used a best-case and
worst-case cost for this policy. The best-case cost assumes that
there are no costs incurred to the industry and therefore is the
same as the cost for voluntary reformulation. The worst-case cost
is calculated using the estimated 20,000 product lines reformu-
lated under the voluntary strategy and the British Retail Con-
sortium’s own estimate of £25,000 for the reformulation of one
product line. We have not explicitly considered the cost of
implementing the legislation in terms of the legal processes
involved, and so it is likely that there may be additional costs
for reformulation, mainly during year one.
The FSA regularly monitors the effect of these policies on salt
intake to ensure that manufacturers are labeling products correctly
and to monitor the current salt content of reformulated foods and
the salt levels of the general population. The cost of monitoring for
each of these policies has been estimated at £2,384,615, reﬂecting
the rolling cost for the urine analysis conducted by the National
Diet and Nutrition Surveys for the FSA and monitoring of nutrition
labels for salt content every 2 years [26].
This cost is assumed to occur every year since the work is
ongoing. There was no monitoring cost associated with the
health promotion campaign (Table 2).
Health Care Costs
The seven mutually exclusive patient groups outlined above were
identiﬁed using the IMPACT CHD model categories. These events
were broken down into treatments, medications, and medical
professional time or visits. Costs were assigned to each treatment
using data from the Department of Health reference costs 2010-
2011 and The Unit Costs of Health and Social Care 2011 [27].
Observed treatment uptake rates were then used to calculate the
unit cost for each patient group and then summed to calculate
the overall health care costs, shown in Table 3.
Table 3 shows that each policy results in lower health care
costs due to the reduction in CHD events from the reduction in
dietary salt intake among the population. It shows that theTable 3 – Ten-year discounted health care costs for
each policy.
Policy Health care costs (£)
Baseline 15,008,250,131
Change4Life 14,574,001,919
Labeling 14,574,001,919
Reformulation—voluntary 14,406,406,793
Reformulation—mandatory (best
case)
14,321,677,353
Reformulation—mandatory (worst
case)
14,321,677,353baseline costs are the most costly, with the health care costs
from mandatory reformulation being the least.
Analysis
Cost-Effectiveness Analysis
A 10-year time horizon was taken from 2010 (the model baseline
year) to 2020. Policy and health care costs were discounted at 3.5%
[28]. The total cost of each policy was calculated as the sum of the
cost of introducing the policy and the total health care costs over the
10 years. For Change4Life, it was assumed that the campaign would,
as previously, be repeated each year; thus, the policy costs were
assumed to be repeated yearly over the 10 years. For the labeling
and reformulation policies, it was assumed that there would be an
initial setup cost in the ﬁrst year and that in the subsequent years
would be a monitoring cost to ensure that standards are main-
tained. Each policy was compared against a baseline of “do nothing,”
where no new policy was in place. For the baseline, the current
number of patients with CHD was extracted from the IMPACT
model. The patient numbers after the policies have been imple-
mented were calculated in the model and these numbers were
assumed to remain at the new level each year for the remainder of
the 10-year period. The number of patients receiving treatments for
hypertension does not change with each policy; therefore, the
patient numbers remain the same throughout; this is based on
previous observations of trends in hypertension prevalence.
Uncertainty Analysis
Probabilistic sensitivity analysis was used for parameter uncer-
tainty. This was explored using Monte Carlo simulation and
involves repeatedly sampling random values from speciﬁed
statistical distributions for the input variables, and then these
values are used to recalculate the model. We used the EXCEL add-
in Ersatz software to perform 1000 runs to determine the 95%
uncertainty intervals of the DPPs (2.5th and 97.5th percentile
values corresponding to the lower and upper limits); more
information is available in Appendix 3 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.03.1722. We plotted
the estimated distribution of incremental LYG and incremental
cost in the cost-effectiveness plane (Fig. 1).
Sensitivity Analysis
The minimum and maximum effectiveness estimates in Table 1
were used in the model to provide the range of possible outcomes
from each policy including a minimum and maximum LYG and
minimum and maximum incremental costs.
Results
The effectiveness estimates for each policy, shown in Table 1, use a
percentage reduction in dietary salt intake from the baseline UK salt
intake of 8.1 g/d. The estimated policy effects on salt intake levels
are shown in Table 4.
Table 4 shows that the best estimate of a 2% dietary salt reduc-
tion is equal to a reduction of approximately 0.16 g/d. This equates
to an intake of 7.94 g/d compared with the baseline of 8.1 g/d in 2011.
Table 5 shows the total discounted cost over 10 years of each
policy, which includes the policy costs and the associated monitor-
ing costs from Table 2 and the health care costs from Table 3.
The resulting patient numbers and the LYG after the imple-
mentation of each policy were calculated using the best-
effectiveness estimates. The total cost for each policy was then
used to calculate the incremental cost for each policy against the
baseline of do nothing.
Fig. 1 – Cost-effectiveness plane, incremental life-years gained against incremental costs.
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the discounted costs saved (incremental costs), and LYG over
baseline. All policies resulted in a LYG over the baseline of do
nothing, and each policy appeared cost saving against the
baseline.Results from Sensitivity Analysis
The minimum and maximum effectiveness estimates from
Table 1 were used in the model to show the potential outcomes
from each policy. The analysis was performed using the same
methods as for the best estimates to calculate total costs and
LYG. Using these estimates for each policy, the total and dis-
counted cost of each policy, the minimum and maximum
discounted costs saved (incremental costs), and LYG are shown
in Tables 7 and 8.Table 4 – Estimated policy effects on decreases in salt in
Policy Estimated reduction by policy
Change4life 2
Labeling 2
Reformulation—voluntary 15
Reformulation—mandatory 20
Table 5 – Discounted costs of each policy over 10 y.
Policy Policy costs
Baseline 0
Change4Life 41,605,237
Labeling 36,851,600
Reformulation—voluntary 17,527,929
Reformulation—mandatory (best case) 17,527,929
Reformulation—mandatory (worst case) 500,619,716Results from Uncertainty Analysis
The cost-effectiveness plane shows the output from the uncertainty
analysis and plots the difference in LYG per patient against the
difference in cost per patient. The outputs of the probabilistic model
are plotted in Figure 1, showing the distribution over the incremen-
tal cost, incremental effect, and the joint cost-effect distribution.
From this we can show that all the policies are cost saving.
Only a few points on the distribution show a positive cost per LYG
for mandatory reformulation using the worst-case costs associ-
ated with the costs to industry.Discussion
Policies to reduce dietary salt intake across England offer an
effective strategy for reducing CHD events and increasingtakes using best estimates (g/d).
(%) Estimated decrease in salt intake (g/d)
Best Min Max
0.16 0.065 0.486
0.16 0.065 0.486
1.21 0.324 1.944
1.62 0.648 3.110
Health care costs (£) Total costs (£)
15,008,250,131 15,008,250,131
14,574,001,919 14,615,607,156
14,574,001,919 14,610,853,519
14,406,406,793 14,423,934,722
14,321,677,353 14,339,205,282
14,321,677,353 14,822,297,070
Table 6 – Results for each policy compared with baseline over 10 y (lower and upper uncertainty intervals).
Policy Total cost
discounted (£)
Discounted costs saved
against baseline (£)
LYG over baseline
Baseline 15,008,250,131
Change4Life 14,615,607,156 392,642,975 1970 (1,209–2,854)
Labeling 14,610,853,519 397,396,612 1970 (1,209–2,854)
Reformulation voluntary 14,423,934,722 584,315,409 14,593 (9,000–21,049)
Reformulation—mandatory (best case) 14,339,205,282 669,044,849 19,365 (11,967–27,887)
Reformulation—mandatory (worst case) 14,822,297,070 185,953,062 19,365 (11,967–27,887)
LYG, life-year gained.
Table 7 – Results for each policy using the minimum estimates over 10 y (lower and upper uncertainty
intervals).
Policy Total cost
discounted (£)
Discounted costs saved
against baseline (£)
LYG
Baseline 15,008,250,131
Change4Life 14,637,168,381 371,081,751 984 (606–1,424)
Labeling 14,632,414,744 375,835,387 984 (606–1,424)
Reformulation—voluntary 14,555,375,106 452,875,025 4,902 (3,024–7,085)
Reformulation—mandatory (best case) 14,484,331,440 523,918,691 9,758 (6,030–14,080)
Reformulation—mandatory (worst case) 14,967,423,227 40,826,904 9,758 (6,030–14,080)
LYG, life-year gained.
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on health care. The biggest estimated savings came from man-
datory reformulation, particularly when assuming a minimal cost
for the private sector. This suggests that implementing legisla-
tion to reduce dietary salt in processed foods offers a valid way to
substantially decrease spending on health care for CHD. Further-
more, the continuing work in progress between the FSA and the
food industry could also result in further savings on health care
expenditure in the future. Although Change4Life and labeling of
food packaging had smaller effectiveness estimates and gained
fewer life-years, they still appear cost saving compared with the
baseline, and might represent useful components of a compre-
hensive strategy aiming to maximize public health gains from
salt reduction.
Strengths and Limitations
Analysis of UK policies that are already in progress allows us to
reinforce the evidence base surrounding population health inter-
ventions. It has also enabled us to obtain actual cost data for each
policy intervention and effectiveness estimates for reformulationTable 8 – Results for each policy using the maximum est
intervals).
Policy Total cost
discounted (£)
Baseline 15,008,250,131
Change4Life 14,579,775,398
Labeling 14,575,021,762
Reformulation—voluntary 14,346,237,671
Reformulation—mandatory (best case) 14,186,428,342
Reformulation—mandatory (worst case) 14,669,520,129
LYG, life-year gained.and Change4Life. We have also included the majority of the
English population for this analysis including all adults aged 25þ
years, which allows us to better capture the overall beneﬁt from
these interventions. The use of probabilistic sensitivity analysis
allows us to account for uncertainty in our parameters and
outcomes, and to generate minimum and maximum estimates
in the model to show a range of the potential outcomes. This
model focuses on health events related to CHD. A reduction,
however, in diabetes and other chronic diseases could also occur
[29]; the total gains may therefore be greater than the current
estimates.
There is inevitably some uncertainty surrounding the costs for
voluntary reformulation and the issue of how best to include
costs to the food industry. These costs were not included in the
FSA Impact Assessment, which reasonably assumed that these
costs would be absorbed in the rolling process of continuous
product reformulation. We wanted, however, to show the overall
potential costs from reformulation using legislation; using two
estimates with and without the cost to the food industry thus
allows us to account for much of this uncertainty. The model
assumes a single step change in policy, moving in one year fromimates over 10 y (lower and upper uncertainty
Discounted cost savings
against baseline (£)
LYG
428,474,733 4,902 (3,048–7,080)
433,228,369 4,902 (3,048–7,080)
662,012,461 19,332 (12,084–27,787)
821,821,789 30,582 (19,198–43,813)
338,730,002 30,582 (19,198–43,813)
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 1 7 – 5 2 4 523the baseline of do nothing to a fully implemented policy in the
next year. In reality, there is likely to be a phased implementation
over time with dietary salt levels reducing over time. Similarly,
the patient numbers were assumed to remain the same in
subsequent years, which is likely to represent an overestimate.
The study does not consider the future health care costs of
people living longer due to avoiding or postponing a CHD event.
It also does not consider the implications of the difference in
taste of the foods and consumers’ preferences for those foods.
There is good evidence to suggest that consumers do not notice
salt reductions in products when the reductions are spread over a
12-month period. People’s taste buds gradually become accus-
tomed to the change in salt content [30]. Observations of real
patient cohorts suggest, however, that longevity delays health
care costs rather than increasing the total [31]. Finally, because
the policies have similar effectiveness estimates, it is difﬁcult to
distinguish the different options from the cost-effectiveness
plane ﬁgure. This does demonstrate, however, that policies are
cost saving.
Comparisons with Other Studies
Our ﬁndings are consistent with results from other modeling
studies. Another UK study by Barton et al. [11] using a very different
methodology estimated that a 3-g reduction in dietary salt intake
could save about £40 million per year. The vast majority of studies
that analyze population health interventions to reduce dietary salt
intake have found that these types of interventions can be cost
saving by substantially reducing the number of CHD events
[9,10,32–35]. Many of these other studies use disability-adjusted
life-years as the health outcome measure. Although we are unable
to directly compare LYG and disability-adjusted life-years results,
most of the studies consistently found that population health
interventions to reduce salt were cost-effective or cost saving. The
level of cost saving is dependent on the cost of the intervention,
which will vary across different settings. For example, the North
Karelia project in Finland showed the cost of the intervention as
ranging from $5 to $17 per head; this resulted in the project ranging
from cost saving (dominant) up to $5900 per QALY depending on
the costs used for the intervention [7]. In our study, the use of the
best- and worst-case cost for mandatory reformulation highlights
this issue where the cost savings are substantially reduced with the
inclusion of cost estimates supplied by the food industry (which
might sometimes be inﬂated). In America, Bibbins-Domingo et al.
[10] estimated that dietary salt reduction of up to 3 g/d might result
in 60,000 fewer CHD cases, approximately 32,000 fewer strokes,
54,000 fewer myocardial infarctions, and 44,000 total deaths annu-
ally. Another US study [36] suggested that a 4-g reduction in dietary
salt intake to 6 g/d (the recommended maximum for adults in
America) might reduce the hypertension prevalence by 28%, repre-
senting 11 million fewer cases in the American population.
Policy Implications
The UK government, the FSA, and NICE have all highlighted the
need to reduce dietary salt intake and have taken the ﬁrst steps.
Similar moves are now happening in many other countries. In
Canada, the issue of dietary salt is highlighted by the recent bill
passed in 2012 called “Sodium Reduction Strategy for Canada”
[37]. In Europe, regulations have already been passed in Finland,
Portugal, and Hungary and are being actively considered else-
where [38]. The use of population health interventions could
reduce health care costs in the future and thus reduce the burden
on the health care system in England and Wales. These results
may be comparable in Scotland given the similarities in cardio-
vascular epidemiology and therefore could reduce the burden on
the health care system in Scotland.Conclusions
Population health interventions that effectively reduce dietary
salt intake in the English population could substantially decrease
health care expenditure and reduce the burden of CVD.
Mandatory reformulation of processed foods might achieve
the biggest reductions in dietary salt intake and therefore the
largest savings.
These ﬁndings are reassuringly consistent with earlier studies
from the United Kingdom and elsewhere.Acknowledgments
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